

# Karen Duff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11480736/publications.pdf>

Version: 2024-02-01

75  
papers

18,164  
citations

36303

51  
h-index

91884

69  
g-index

75  
all docs

75  
docs citations

75  
times ranked

15385  
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-invasive, Focused Ultrasound-Facilitated Gene Delivery for Optogenetics. <i>Scientific Reports</i> , 2017, 7, 39955.	3.3	53
2	Global Axonal Transport Rates are Unaltered in Htau Mice in vivo. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 579-586.	2.6	14
3	Contrasting Pathology of the Stress Granule Proteins TIA-1 and G3BP in Tauopathies. <i>Journal of Neuroscience</i> , 2012, 32, 8270-8283.	3.6	186
4	The phospholipase D1 pathway modulates macroautophagy. <i>Nature Communications</i> , 2010, 1, 142.	12.8	161
5	Age-Dependent Impairment of Cognitive and Synaptic Function in the htau Mouse Model of Tau Pathology. <i>Journal of Neuroscience</i> , 2009, 29, 10741-10749.	3.6	306
6	Optical visualization of Alzheimer's pathology via multiphoton-excited intrinsic fluorescence and second harmonic generation. <i>Optics Express</i> , 2009, 17, 3679.	3.4	94
7	Altered Calcium Homeostasis and Mitochondrial Dysfunction in Cortical Synaptic Compartments of Presenilin-1 Mutant Mice. <i>Journal of Neurochemistry</i> , 2008, 72, 1030-1039.	3.9	144
8	A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. <i>Neurobiology of Disease</i> , 2008, 31, 46-57.	4.4	92
9	A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse. <i>Journal of Visualized Experiments</i> , 2008, , .	0.3	207
10	Linking A $\beta$ 2 and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis. <i>Neuron</i> , 2008, 60, 534-542.	8.1	465
11	New directions for frontotemporal dementia drug discovery. , 2008, 4, 89-93.		29
12	Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and A $\beta$ 2 accumulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7327-7332.	7.1	230
13	Cdk5 and Neuregulin-1 Signaling. , 2008, , 139-144.		0
14	Antibody against C-terminal Abeta selectively elevates plasma Abeta. <i>NeuroReport</i> , 2007, 18, 293-296.	1.2	17
15	Collapsin response mediator protein $\beta$ 2 hyperphosphorylation is an early event in Alzheimer's disease progression. <i>Journal of Neurochemistry</i> , 2007, 103, 1132-1144.	3.9	158
16	The amyloid pathology progresses in a neurotransmitter-specific manner. <i>Neurobiology of Aging</i> , 2006, 27, 1644-1657.	3.1	129
17	Normal and Abnormal Tau Neurobiology. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 202-205.	1.3	6
18	Cholesterol Distribution, Not Total Levels, Correlate With Altered Amyloid Precursor Protein Processing in Statin-Treated Mice. <i>NeuroMolecular Medicine</i> , 2006, 8, 319-328.	3.4	52

#	ARTICLE	IF	CITATIONS
19	Using proteomics and network analysis to elucidate the consequences of synaptic protein oxidation in a PS1+A $\beta$ PP mouse model of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2005, 8, 227-241.	2.6	24
20	Untangling memory deficits. <i>Nature Medicine</i> , 2005, 11, 826-827.	30.7	42
21	An A $\beta$ Sequestration Approach Using Non-Antibody A $\beta$ Binding Agents. <i>Current Alzheimer Research</i> , 2005, 2, 265-268.	1.4	9
22	Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration <i>in vivo</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 6990-6995.	7.1	649
23	Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms. <i>Journal of Neuroscience</i> , 2005, 25, 5446-5454.	3.6	481
24	Dense-Core Plaques in Tg2576 and PSAPP Mouse Models of Alzheimer's Disease Are Centered on Vessel Walls. <i>American Journal of Pathology</i> , 2005, 167, 527-543.	3.8	168
25	Macroautophagy a novel A $\beta$ -amyloid peptide-generating pathway activated in Alzheimer's disease. <i>Journal of Cell Biology</i> , 2005, 171, 87-98.	5.2	891
26	Rat transgenic models with a phenotype of intracellular A $\beta$ accumulation in hippocampus and cortex. <i>Journal of Alzheimer's Disease</i> , 2004, 6, 209-219.	2.6	70
27	Amyloid- $\beta$ Deposition Is Associated with Decreased Hippocampal Glucose Metabolism and Spatial Memory Impairment in APP/PS1 Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 418-428.	1.7	111
28	Transgenic mouse models of Alzheimer's disease: How useful have they been for therapeutic development?. <i>Briefings in Functional Genomics &amp; Proteomics</i> , 2004, 3, 47-59.	3.8	90
29	Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. <i>Nature Neuroscience</i> , 2004, 7, 1181-1183.	14.8	497
30	Links Between the Pathology of Alzheimer's Disease and Vascular Dementia. <i>Neurochemical Research</i> , 2004, 29, 1257-1266.	3.3	89
31	MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. <i>Magnetic Resonance in Medicine</i> , 2004, 51, 794-798.	3.0	108
32	Visualization of A $\beta$ -amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. <i>Magnetic Resonance in Medicine</i> , 2004, 52, 538-544.	3.0	99
33	In Vivo Magnetic Resonance of Amyloid Plaques in Alzheimer's Disease Model Mice. , 2004, , 47-59.		3
34	Rapid Neurofibrillary Tangle Formation after Localized Gene Transfer of Mutated Tau. <i>American Journal of Pathology</i> , 2004, 164, 347-353.	3.8	44
35	Mostly Separate Distributions of CLAC- versus A $\beta$ 40- or Thioflavin S-Reactivities in Senile Plaques Reveal Two Distinct Subpopulations of A $\beta$ -Amyloid Deposits. <i>American Journal of Pathology</i> , 2004, 165, 273-281.	3.8	30
36	Loss of Presenilin Function Causes Impairments of Memory and Synaptic Plasticity Followed by Age-Dependent Neurodegeneration. <i>Neuron</i> , 2004, 42, 23-36.	8.1	701

#	ARTICLE	IF	CITATIONS
37	Presenilin Mutations in Familial Alzheimer Disease and Transgenic Mouse Models Accelerate Neuronal Lysosomal Pathology. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 821-830.	1.7	139
38	Changes in Apolipoprotein E Expression in Response to Dietary and Pharmacological Modulation of Cholesterol. <i>Journal of Molecular Neuroscience</i> , 2003, 20, 395-406.	2.3	47
39	Brain Damage Results in Down-Regulation of N-Acetylaspartate as a Neuronal Osmolyte. <i>NeuroMolecular Medicine</i> , 2003, 3, 95-104.	3.4	32
40	Use of in vivo models to study the role of cholesterol in the etiology of Alzheimer's disease. <i>Neurochemical Research</i> , 2003, 28, 979-986.	3.3	21
41	Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. <i>Magnetic Resonance in Medicine</i> , 2003, 50, 293-302.	3.0	267
42	Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. <i>Journal of Neurochemistry</i> , 2003, 86, 582-590.	3.9	662
43	Co-localization of cholesterol, apolipoprotein E and fibrillar A $\beta$ in amyloid plaques. <i>Molecular Brain Research</i> , 2003, 110, 119-125.	2.3	108
44	Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo. <i>Neuron</i> , 2003, 38, 555-565.	8.1	474
45	Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to $\beta$ -Amyloid. <i>Journal of Neuroscience</i> , 2003, 23, 29-33.	3.6	332
46	Presenilin Redistribution Associated with Aberrant Cholesterol Transport Enhances $\beta$ -Amyloid Production In Vivo. <i>Journal of Neuroscience</i> , 2003, 23, 5645-5649.	3.6	170
47	Statin therapy for Alzheimer's disease. <i>Journal of Molecular Neuroscience</i> , 2002, 19, 155-161.	2.3	152
48	Cholesterol in Alzheimer's Disease and Tauopathy. <i>Annals of the New York Academy of Sciences</i> , 2002, 977, 367-375.	3.8	116
49	Organotypic Slice Cultures from Transgenic Mice as Disease Model Systems. <i>Journal of Molecular Neuroscience</i> , 2002, 19, 317-320.	2.3	32
50	Permeability of Proteins at the Blood-Brain Barrier in the Normal Adult Mouse and Double Transgenic Mouse Model of Alzheimer's Disease. <i>Neurobiology of Disease</i> , 2001, 8, 555-567.	4.4	110
51	Inflammatory Responses to Amyloidosis in a Transgenic Mouse Model of Alzheimer's Disease. <i>American Journal of Pathology</i> , 2001, 158, 1345-1354.	3.8	275
52	Transgenic mouse models of Alzheimer's disease: phenotype and mechanisms of pathogenesis. <i>Biochemical Society Symposia</i> , 2001, 67, 195-202.	2.7	24
53	Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. <i>NeuroReport</i> , 2001, 12, 1377-1384.	1.2	65
54	Progress in the modeling of neurodegenerative diseases in transgenic mice. <i>Current Opinion in Neurology</i> , 2001, 14, 441-447.	3.6	21

#	ARTICLE	IF	CITATIONS
55	Plaque-Induced Abnormalities in Neurite Geometry in Transgenic Models of Alzheimer Disease: Implications for Neural System Disruption. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 753-758.	1.7	88
56	Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. <i>Nature Genetics</i> , 2000, 25, 402-405.	21.4	1,254
57	A $\beta$ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. <i>Nature</i> , 2000, 408, 982-985.	27.8	1,506
58	Functional Phenotype in Transgenic Mice Expressing Mutant Human Presenilin-1. <i>Neurobiology of Disease</i> , 2000, 7, 119-126.	4.4	68
59	Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model. <i>Neurobiology of Disease</i> , 2000, 7, 321-331.	4.4	964
60	Age-Related Amyloid $\beta$ Deposition in Transgenic Mice Overexpressing Both Alzheimer Mutant Presenilin 1 and Amyloid $\beta$ Precursor Protein Swedish Mutant Is Not Associated with Global Neuronal Loss. <i>American Journal of Pathology</i> , 2000, 157, 331-339.	3.8	222
61	Transgenic Mice Overexpressing Presenilin cDNAs. , 2000, , 123-128.		0
62	Reorganization of Cholinergic Terminals in the Cerebral Cortex and Hippocampus in Transgenic Mice Carrying Mutated Presenilin-1 and Amyloid Precursor Protein Transgenes. <i>Journal of Neuroscience</i> , 1999, 19, 2706-2716.	3.6	193
63	A Loss of Function Mutation of Presenilin-2 Interferes with Amyloid $\beta$ -Peptide Production and Notch Signaling. <i>Journal of Biological Chemistry</i> , 1999, 274, 28669-28673.	3.4	279
64	5' Splice Site Mutations in tau Associated with the Inherited Dementia FTDP-17 Affect a Stem-Loop Structure That Regulates Alternative Splicing of Exon 10. <i>Journal of Biological Chemistry</i> , 1999, 274, 15134-15143.	3.4	266
65	Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. <i>Behavior Genetics</i> , 1999, 29, 177-185.	2.1	320
66	Chapter 5.8 Transgenic mouse models of Alzheimer's disease. <i>Handbook of Behavioral Neuroscience</i> , 1999, , 880-894.	0.0	1
67	Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. <i>Nature Neuroscience</i> , 1998, 1, 355-358.	14.8	310
68	Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. <i>Nature Medicine</i> , 1998, 4, 97-100.	30.7	1,288
69	Increased A $\beta$ 42(43) from cell lines expressing presenilin 1 mutations. <i>Annals of Neurology</i> , 1998, 43, 256-258.	5.3	117
70	Recent work on Alzheimer's disease transgenics. <i>Current Opinion in Biotechnology</i> , 1998, 9, 561-564.	6.6	21
71	Alzheimer transgenic mouse models come of age. <i>Trends in Neurosciences</i> , 1997, 20, 279-280.	8.6	28
72	Increased amyloid- $\beta$ 42(43) in brains of mice expressing mutant presenilin 1. <i>Nature</i> , 1996, 383, 710-713.	27.8	1,480

#	ARTICLE	IF	CITATIONS
73	A mutation in Alzheimer's disease destroying a splice acceptor site in the presenilin-1 gene. NeuroReport, 1995, 7, 297-301.	1.2	262
74	In Vivo Perturbation of Lysosomal Function Promotes Neurodegeneration in the PS1M146V/APPK670N,M671L Mouse Model of Alzheimer's Disease Pathology. , 0, , 687-695.		1
75	Animal Models of Tauopathy. , 0, , 215-236.		0